The most recent trading session ended with Novo Nordisk (NVO) standing at $80.57, reflecting a -0.57% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.61% gain on the ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

Novo Nordisk Expands AI Partnership With Valo Health for Development of Obesity Drugs (Reuters) - Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding ...